Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials

AIM: To assess the effect of empagliflozin on cardiovascular (CV) risk in patients with type 2 diabetes (T2DM) through a meta‐analysis of data from eight placebo‐controlled trials. METHODS: Data were analysed from eight randomized placebo‐controlled trials undertaken to investigate the efficacy and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Salsali, A., Kim, G., Woerle, H. J., Broedl, U. C., Hantel, S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2016
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5096016/
https://ncbi.nlm.nih.gov/pubmed/27376831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12734
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky